alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>

                                                                Exhibit 8.1

                             LIST OF SUBSIDIARIES

DIRECT SUBSIDIARIES                             COUNTRY OF FORMATION

Nera Broadband Satellite AS                        Norway
Nera Finans AS                                     Norway
Nera Networks AS                                   Norway
Nera Satcom AS                                     Norway
Nera Telecommunicaciones Latin-America SA          Venezuela
Nera Telecommunications Ltd.                       Singapore
Nera WBA AS                                        Norway
Nera WBA Satellite AS                              Norway

INDIRECT SUBSIDIARIES                              COUNTRY OF FORMATION

Beijing Nera Stentofon Comm. Co. Ltd.              China
Nera America Latina Ltda                           Brazil
Nera America Latina Ltda Sucursal Colombia         Colombia
Nera Americas Holding                              USA
Nera Americas Inc.                                 USA
Nera de Mexico SA de CV                            Mexico
Nera Electronics (S) Pte Ltd.                      Singapore
Nera GmbH                                          Germany
Nera (HK) Ltd.                                     Hong Kong
Nera (India) Ltd.                                  India
Nera Infocom (M) Sdh Bhd                           Malaysia
Nera (Malaysia) Sdn Bhd                            Malaysia
Nera Mechatronics AS                               Norway
Nera Networks Inc.                                 USA
Nera (Philippines) Inc.                            Philippines
Nera (Thailand) Ltd.                               Thailand
Nera Telecommunications Inc.                       USA
Nera Telecommunications (Taiwan) Co, Ltd.          Taiwan
PT Nera Indonesia                                  Indonesia
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3130 Clostridium difficile toxin gene amplification assay. ( a ) *Identification.* A *Clostridium difficile* toxin gene amplification assay is a device that consists of reagents for the amplification and detection of target sequences in *Clostridium difficile* toxin genes in fecal specimens from patients suspected of having *Clostridium difficile* infection (CDI). The detection of clostridial toxin genes, in conjunction with other laboratory tests, aids in the clinical laboratory diagnosis of CDI caused by *Clostridium difficile.*
( b ) *Classification.* Class II (special controls). The special controls are set forth in FDA's guideline document entitled: “Class II Special Controls Guideline: Toxin Gene Amplification Assays for the Detection of *Clostridium difficile;* Guideline for Industry and Food and Drug Administration Staff.” See § 866.1(e) for information on obtaining this document.
[80 FR 51939, Aug. 27, 2015]
Exhibit 35.2  LOGO ANNUAL STATEMENT OF COMPLIANCE OF LNR PARTNERS, LLC The undersigned, Job Warshaw,
being the President of LNR Partners, LLC (the Special Servicer), as special servicer under the applicable Pooling and Servicing Agreement for the transactions listed on Schedule Ihereto, hereby certifies, subject to any
limitations listed on Schedule Ihereto, as of the date hereof, on behalf of the Special Servicer, solely in his capacity as an authorized officer of the Special Servicer and not in his individual capacity, as follows:  1.
A review of the activities performed by the Special Servicer during the period commencing on January 1, 2018
and ending on December 31, 2018 (or any other shorter period set forth on Schedule Ihereto) (the Reporting Period), and of the Special Servicers performance under the Pooling and Servicing Agreement has been made under my
supervision; and  2.
To the best of my knowledge, based on such review and using the applicable servicing criteria under Item 1122
of Regulation AB, the Special Servicer has fulfilled all of its obligations under the applicable Pooling and Servicing Agreement in all material respects throughout the Reporting Period.  LNR PARTNERS, LLC, a Florida
limited liability companyBy: \s\ Job WarshawJob WarshawPresident
 Dated: February 19, 2019   1601 Washington Avenue ● Suite 700 ● Miami Beach, Florida 33139-3164 Telephone: (305) 695-5600 ● Fax: (305)
695-5601




---

Schedule I CGCMT 2015-P1 Citigroup Commercial Mortgage Trust 2015-P1, Commercial Mortgage Pass-Through Certificates, Series 2015- P1 Citibank,N.A., Global Transaction Services 388 Greenwich Street, 14th Floor New York NY 10013 Cirino Emanuele Citibank,N.A., Global Transaction Services 388 Greenwich Street, 14th Floor New York NY 10013 John Hannon Citigroup Commercial Mortgage Securities Inc. 390 Greenwich Street, 5th Floor New York NY 10013 Paul Vanderslice Citigroup Commercial Mortgage Securities Inc. 388 Greenwich Street, 19th Floor New York NY 10013 Richard Simpson Citigroup Commercial Mortgage Securities Inc. 388 Greenwich Street, 17th Floor New York NY 10013 Ryan M. OConnor Deutsche Bank National Trust Company Trust & Agency Services 1761 E. Saint Andrew Place Santa Ana CA 92705 James Noriega Park Bridge Lender Services LLC 600 Third Avenue, 40th Floor New York NY 10016 David Rodgers Park Bridge Lender Services LLC 600 Third Avenue, 40th Floor New York NY 10016 Attn: CGCMT 2015-P1
[Federal Register Volume 75, Number 42 (Thursday, March 4, 2010)]
[Notices]
[Page 9910]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4481]



[[Page 9910]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Eunice Kennedy Shriver National Institute of Child Health & Human 
Development; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel, Laboratory Support for the 
Division of Epidemiology, Statistics and Prevention-I and II.
    Date: March 24, 2010.
    Time: 2 p.m. to 3:30 p.m.
    Agenda: To provide concept review of proposed concept review.
    Place: National Institutes of Health, 6100 Executive Boulevard, 
Room 5B01, Rockville, MD 20852. (Telephone Conference Call.)
    Contact Person: Sathasiva B. Kandasamy, PhD, Scientific Review 
Officer, Division of Scientific Review, Eunice Kennedy Shriver 
National Institute of Child Health and Human Development, 6100 
Executive Boulevard, Room 5B01, Bethesda, MD 20892-9304. (301) 435-
6680.<a href="/cdn-cgi/l/email-protection#2b58404a454f4a584a6b464a424705454243054c445d"><span class="__cf_email__" data-cfemail="ea99818b848e8b998baa878b8386c4848382c48d859c">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, 
Population Research; 93.865, Research for Mothers and Children; 
93.929, Center for Medical Rehabilitation Research; 93.209, 
Contraception and Infertility Loan Repayment Program, National 
Institutes of Health, HHS)

    Dated: February 25, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4481 Filed 3-3-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
I 

118TH CONGRESS 

2D SESSION H. R. 7676 

To amend title 18, United States Code, to prohibit officers and employees 

of the judiciary from engaging in official acts affecting personal financial 

interests. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 13, 2024 

Mr. SCHIFF (for himself, Mr. JOHNSON of Georgia, Ms. NORTON, Ms. LEE

of California, Mr. GOLDMAN of New York, Mr. JACKSON of Illinois, and 

Mrs. RAMIREZ) introduced the following bill; which was referred to the 

Committee on the Judiciary 

A BILL 

To amend title 18, United States Code, to prohibit officers 

and employees of the judiciary from engaging in official 

acts affecting personal financial interests. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Judicial Integrity 

5 Act’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7676 IH

1 SEC. 2. ACTS AFFECTING A PERSONAL FINANCIAL INTER2 EST. 

3 (a) JUDICIAL CONFLICTS OF INTEREST.—Section 

4 208(a) of title 18, United States Code, is amended by in5 serting after ‘‘of the United States Government,’’ the fol6 lowing: ‘‘or of the judicial branch of the United States 

7 Government, including a Federal judge or a justice of the 

8 Supreme Court of the United States,’’. 

9 (b) REGULATORY WAIVER.—Section 208(b) of title 

10 18, United States Code, is amended— 

11 (1) in paragraph (3), by striking ‘‘or’’ at the 

12 end; 

13 (2) in paragraph (4), by striking ‘‘parties.’’ and 

14 inserting ‘‘parties; or’’ ; and 

15 (3) by adding at the end the following: 

16 ‘‘(5) if, by regulation issued by the Judicial 

17 Conference of the United States applicable to all ju18 dicial officers and employees covered by this section, 

19 with public notice and comment, the financial inter20 est has been exempted from the requirements of sub21 section (a) as being too remote or too inconsequen22 tial to affect the integrity of the services of the Gov23 ernment officers or employees to which such regula24 tion applies.’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                           18336
<SECURITIES>                                       590
<RECEIVABLES>                                     1469
<ALLOWANCES>                                         0
<INVENTORY>                                        157
<CURRENT-ASSETS>                                 21950
<PP&E>                                            3489
<DEPRECIATION>                                    1913
<TOTAL-ASSETS>                                   27269
<CURRENT-LIABILITIES>                            10323
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            68
<OTHER-SE>                                       27202
<TOTAL-LIABILITY-AND-EQUITY>                     27269
<SALES>                                              0
<TOTAL-REVENUES>                                 18843
<CGS>                                                0
<TOTAL-COSTS>                                    14190
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   2
<INCOME-PRETAX>                                   5981
<INCOME-TAX>                                      2034
<INCOME-CONTINUING>                               3947
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                      3947
<EPS-PRIMARY>                                       .6
<EPS-DILUTED>                                       .6


</TABLE>
[ARTICLE] 5
<TABLE>
<S>                             <C>
[PERIOD-TYPE]                   9-MOS
[FISCAL-YEAR-END]                          DEC-31-1996
[PERIOD-END]                               SEP-30-1996
[CASH]                                               0
[SECURITIES]                                         0
[RECEIVABLES]                                9,356,114
[ALLOWANCES]                                   166,772
[INVENTORY]                                  5,064,889
[CURRENT-ASSETS]                            14,955,475
[PP&E]                                         409,573
[DEPRECIATION]                                 103,921
[TOTAL-ASSETS]                              15,365,048
[CURRENT-LIABILITIES]                       11,823,291
[BONDS]                                              0
[PREFERRED-MANDATORY]                                0
[PREFERRED]                                          0
[COMMON]                                         7,705
[OTHER-SE]                                   2,880,198
[TOTAL-LIABILITY-AND-EQUITY]                15,365,048
[SALES]                                     18,144,695
[TOTAL-REVENUES]                            18,144,695
[CGS]                                       10,515,448
[TOTAL-COSTS]                               10,515,448
[OTHER-EXPENSES]                             5,601,849
[LOSS-PROVISION]                                     0
[INTEREST-EXPENSE]                             363,865
[INCOME-PRETAX]                              1,663,532
[INCOME-TAX]                                   828,513
[INCOME-CONTINUING]                                  0
[DISCONTINUED]                                       0
[EXTRAORDINARY]                                      0
[CHANGES]                                            0
[NET-INCOME]                                   835,019
[EPS-PRIMARY]                                     0.11
[EPS-DILUTED]                                     0.08
</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
FINANCIAL STATEMENTS INCLUDED IN FORM 10-QSB AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                         192,686
<SECURITIES>                                    17,080
<RECEIVABLES>                                6,846,962
<ALLOWANCES>                                 3,941,839
<INVENTORY>                                    351,606
<CURRENT-ASSETS>                             3,497,407
<PP&E>                                       2,249,483
<DEPRECIATION>                                 595,213
<TOTAL-ASSETS>                              18,766,926
<CURRENT-LIABILITIES>                        5,035,453
<BONDS>                                      7,989,595
<PREFERRED-MANDATORY>                           28,923
<PREFERRED>                                    739,696
<COMMON>                                    20,336,291
<OTHER-SE>                                (15,363,032)
<TOTAL-LIABILITY-AND-EQUITY>                18,766,926
<SALES>                                      4,299,489
<TOTAL-REVENUES>                             4,311,170
<CGS>                                        3,001,892
<TOTAL-COSTS>                                4,451,568
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             250,492
<INCOME-PRETAX>                              (390,890)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (390,890)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (390,890)
<EPS-PRIMARY>                                   (0.11)
<EPS-DILUTED>                                   (0.11)
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          AUG-31-1997
<PERIOD-START>                             SEP-01-1996
<PERIOD-END>                               AUG-31-1997
<CASH>                                       1,766,274
<SECURITIES>                                   978,463
<RECEIVABLES>                                2,250,168
<ALLOWANCES>                                   130,000
<INVENTORY>                                  7,889,949
<CURRENT-ASSETS>                            13,636,227
<PP&E>                                      12,923,242
<DEPRECIATION>                               8,765,160
<TOTAL-ASSETS>                              18,225,900
<CURRENT-LIABILITIES>                        3,693,112
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        53,038
<OTHER-SE>                                  12,830,392
<TOTAL-LIABILITY-AND-EQUITY>                18,225,900
<SALES>                                     33,634,248
<TOTAL-REVENUES>                            33,634,248
<CGS>                                       29,927,909
<TOTAL-COSTS>                               29,927,909
<OTHER-EXPENSES>                             (200,738)
<LOSS-PROVISION>                               130,000
<INTEREST-EXPENSE>                             275,057
<INCOME-PRETAX>                              (484,378)
<INCOME-TAX>                                   (7,623)
<INCOME-CONTINUING>                          (476,755)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (476,755)
<EPS-PRIMARY>                                    (.09)
<EPS-DILUTED>                                    (.09)
        

</TABLE>
| (logo)  **ncb**  National Cooperative Bank    | 2011  Crystal Drive  Suite, 8oo  Arlington, VA 22202 |
|----------------------------------------------------|-----------------------------------------------------------|

 

 

#  February 6, 2019

 

WellsFargo Commercial Mortgage Securities, Inc. as Depositor

Attn:AJ Sfarra

375Park Avenue, 2nd Floor

J0127-023

NewYork, NY 10152

 

RE:         Annual Statement as to Compliance

               WFCM 2015 C30

 

DearSir/Madam:

 

Inaccordance with the Pooling and Servicing Agreement entered into in connectionwith the issuance of the Commercial Mortgage Pass-Through Certificates Series2015-C30, as an authorized officer of National Cooperative Bank, N.A., formerlyNCB, FSB (the “NCB Special Servicer”), I hereby certify pursuant to Section11.12 thereof that:

 

a.       A review of the activities of the NCB Special Servicer during the precedingcalendar year (the “Reporting Period”) and of its performance under the Poolingand Servicing Agreement has been made under my supervision.

 

b.       To the best of my knowledge, based on these reviews, the NCB Special Servicerhas fulfilled all obligations under this agreement in all material respectsthroughout the Reporting Period.

 

Pleasenote that the annual financial statement will be sent under separate cover onor before March 31, 2019.

 

 

Bestregards,

/s/Karyn Mann

KarynMann

SeniorVice President, Investor Compliance

NationalCooperative Bank, N.A.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1820 Xylose test system. ( a ) *Identification.* A xylose test system is a device intended to measure xylose (a sugar) in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of gastrointestinal malabsorption syndrome (a group of disorders in which there is subnormal absorption of dietary constituents and thus excessive loss from the body of the nonabsorbed substances).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2308, Jan. 14, 2000]
Editorial Note on Part 860
Editorial Note: Nomenclature changes to part 860 appear at 73 FR 35341, June 23, 2008, and at 86 FR 54846, Oct. 5, 2021.

§ 860.123 Reclassification petition: Content and form. ( a ) Unless otherwise provided in writing by the Commissioner, any petition for reclassification of a device, regardless of the section of the Federal Food, Drug, and Cosmetic Act under which it is filed, shall include the following: ( 1 ) A specification of the type of device for which reclassification is requested;
( 2 ) A statement of the action requested by the petitioner, e.g., “It is requested that _ device(s) be reclassified from class III to a class II”;
( 3 ) A statement of the basis for disagreement with the present classification status of the device;
( 4 ) A full statement of the reasons, together with supporting data satisfying the requirements of § 860.7, why the device should not be classified into its present classification and how the proposed classification will provide reasonable assurance of the safety and effectiveness of the device;
( 5 ) Representative data and information known by the petitioner that are unfavorable to the petitioner's position;
( 6 ) If the petition is based upon new information under section 513(e), 514(b), or 515(b) of the Federal Food, Drug, and Cosmetic Act, a summary of the new information;
( 7 ) Copies of source documents from which new information used to support the petition has been obtained (attached as appendices to the petition); and
( 8 ) A financial certification or disclosure statement or both as required by part 54 of this chapter.
( b ) Each petition submitted pursuant to this section shall be: ( 1 ) For devices regulated by the Center for Devices and Radiological Health, addressed to the Food and Drug Administration, Center for Devices and Radiological Health, Office of Policy Staff, 10903 New Hampshire Ave., Bldg. 66, Rm. 5445, Silver Spring, MD 20993-0002; for devices regulated by the Center for Biologics Evaluation and Research, addressed to the Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002; for devices regulated by the Center for Drug Evaluation and Research, addressed to the Food and Drug Administration, Center for Drug Evaluation and Research, Central Document Control Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266, as applicable.
( 2 ) Marked clearly with the section of the Federal Food, Drug, and Cosmetic Act under which the petition is being submitted, *i.e.,* “513(e),” “513(f)(3),” “514(b),” “515(b),” or “520(*l*) Petition”;
( 3 ) Bound in a volume or volumes, where necessary; and
( 4 ) Submitted in an original and two copies.
[43 FR 32993, July 28, 1978, as amended at 49 FR 14505, Apr. 12, 1984; 53 FR 11253, Apr. 6, 1988; 55 FR 11169, Mar. 27, 1990; 63 FR 5254, Feb. 2, 1998; 65 FR 17137, Mar. 31, 2000; 73 FR 49942, Aug. 25, 2008; 75 FR 20916, Apr. 22, 2010; 79 FR 77388, Dec. 24, 2014; 82 FR 39535, Aug. 21, 2017; 83 FR 64456, Dec. 17, 2018; 85 FR 18443, Apr. 2, 2020]